Navigation Links
Companies Pay a High Price for Employees With Crohn's Disease and Ulcerative Colitis, According to Study From Thomson Reuters
Date:11/10/2008

ANN ARBOR, Mich., Nov. 10 /PRNewswire/ -- A study published today in the Journal of Occupational and Environmental Medicine found that annual medical expenditures for Crohn's disease patients are more than three times higher than those for a matched comparison group of patients. Similar results were found for people with ulcerative colitis.

The study examined both direct medical costs - inpatient and outpatient hospital care, office visits, emergency room visits, and prescription drugs - and indirect costs - absenteeism and short-term disability expenses - for patients with employer-sponsored health insurance. Annual medical expenses for Crohn's disease patients were $18,963 versus $5,300 for a matched comparison group. Ulcerative colitis patients' annual medical expenses were $15,020 versus $4,982 for the matched comparison group.

Over 1 million individuals in the United States are affected by Crohn's disease and ulcerative colitis, which are inflammatory bowel diseases. Many are first affected in their 20s and 30s, during prime working years.

In severe cases, gastrointestinal surgery can be warranted, resulting in high costs. Annual medical costs for patients with a gastrointestinal surgery were $60,147 for patients with Crohn's disease and $72,415 for patients with ulcerative colitis.

Patient samples for the study were selected from the Thomson Reuters MarketScan(R) databases representing the healthcare experience of almost 100 large U.S. employers. Patients who had an episode of Crohn's disease or ulcerative colitis (involving at least one inpatient admission, one emergency room visit or two outpatient visits) were matched with patients with no indication of either disease but similar in other respects (demographic, health plan, location, and health status characteristics).

The Healthcare business of Thomson Reuters conducted the research in collaboration with researchers from the University of Illinois at Chicago, Emory
'/>"/>

SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Modern Healthcare Names The Beryl Companies One of Best Places to Work in Healthcare
2. Accuray Incorporated Ranked Fifth in Deloittes Technology Fast 50 Program for Silicon Valley Scientific/Medical Equipment, and Biotechnology Companies
3. Companies Turn to Click-to-Chat Technology to Reduce Operating Expense and Enhance Customer Service
4. Four Companies Are First to Achieve Accreditation Under Two New URAC Pharmacy Quality Management(SM) Programs
5. The Beryl Companies Launches CARE Calls Program in Five Hospitals Across U.S.
6. Cadient Group Named to the Philadelphia 100(R) as One of the Regions Fastest-Growing Privately-Held Companies
7. Credit Card Companies Accomplices in Millions of Identity Theft Cases Alleges Eric Drew
8. Global Intelligence Alliance Strengthens Group Organization and Adds Local Presence, Merges With Asian, German and Dutch Partner Companies
9. The Beryl Companies Named to Inc. 5000 List for Second Consecutive Year
10. Philadelphia Insurance Companies Slam Dunk for Cancer
11. Moog Unifies Its Medical Device Products and Companies Under One Brand

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...NTURA,Fla.,Nov.25/PRNewswire/--DanielTouizer,CEOof...ranteedissuehealthinsurancebenefitprograms,isconce...bermeansnearlyoneinfiveAmericansarewithoutafull-ti...unemploymentratesaredeterminedbytheU-6number,which... Dani e l T ouizer ."Thesestatisticsarealarm...
(Date:11/25/2009)...ease is available in French and Spanish . ,... have provided an early diagnosis of certain ocul...e-related macular degeneration and keratitis, by a...heless, had never before been used for this purpos...image quality in subjects affected by one of these...
(Date:11/25/2009)...ss release is available in French . , , Mont... are about to enter the marketplace, thanks to a n...artnership (Univalor) and Cognitive Sensing Inc. (...n Montreal. , Univalor, which commercializes dis...iliated institutions, and CSI have announced the s...
(Date:11/25/2009)...n fruit fly study may lead to new drugs for people... (HealthDay News) -- Sphingadienes, natural lipid ...ent in treatments for colon cancer, California res...inary, but the study authors pointed out that they...ction against colon cancer. , In the study, Dr....
(Date:11/25/2009)... offer waistline-friendly ways to enjoy festive fe... News) -- If you love the five-week holiday smorga...eady stressing about the added pounds you,ll have ...,s possible, say nutrition experts, to enjoy holid...as you do today. , It,s all about devising a s...
Breaking Medicine News(10 mins):Health News:Cinergy Health Commentary on Health Care for the Unemployed 2Health News:Achieve early diagnosis of ocular pathologies such as keratitis and macular degeneration 2Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2Health News:Natural Soy Component May Help Treat Colon Cancer 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3
...-Year Growth Since Founded, YARDLEY, Pa., April 1...of corporate performance management solutions, tod... BTI has grown its services,revenue year- over-yea...technology or a,business process solution," said T...
...Civility Mutual, based in,Santa Fe, New Mexico, la...nization to offer education, training and CMEs for...and provides residency directors with the,educatio...gins with effective communication, driven by,respe...
...s April 15, 2008 Elderly patients who use antips...developing pneumonia compared to non-users. This r...ption and decreases gradually thereafter. These fi...f psychosis and behavioral problems associated wit...
... Open Biosystems, Inc.,focused on the commerciali... for drug discovery, today announced the availabil...or multiplexed RNAi screens. This,novel offering a...onal sequencing., (Logo: http://www.newscom.com/...
... /Xinhua-PRNewswire-FirstCall/ -- CNinsure,Inc. CI...kerage company,operating in China, today announced...ship with Minsheng Life Insurance Co., Ltd ("Minsh...d local branch,levels to further promote the busin...
..., 2008 -- Results of a phase IV, open label, head-...e, high-frequency subcutaneous Rebif (interferon b...gs show similar efficacy over 18 to 30 months of c...cal Research and Opinion journal. , The Prospecti...
Other Medicine News:Health News:Breakaway Technologies Celebrates 10 Years in Business 2Health News:New Health Care Company to Offer Training and CMEs on Physician - Patient Communications and Helps Fulfill ACGME Requirements 2Health News:Open Biosystems Launches Decode RNAi Viral Screening Pools for Low-Cost Genome-Scale RNAi Screens 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 2Health News:CNinsure Enters Into Strategic Partnership With Minsheng Life Insurance 3Health News:Study shows that high-dose, high-frequency interferon produces no additional benefit 2
(Date:11/24/2009)..., IRVINE,Calif.,Nov.24/PRNewswire-FirstCall/-...yinvasivetreatmentsforaorticdisorders,announcedtod...eedingsin,thepatentinfringementlawsuitbroughtagain...UnitedStatesDistrictCourtinIndianapolis,Indiana. ,...twhiletheUnitedStatesPatentandTrademarkOffice(USPT...
(Date:11/24/2009)..., FREMONT,Calif.,Nov.24/PRNewswire-FirstCall/...theCompanyfileditsPlanofReorganizationandDisclosur...sBankruptcyCourtfortheDistrictofDelaware.Ahearingt...lyscheduledforDecember8,2009,withthehearingontheco..., ThePlancallsfortheCompanytopayallclaimsinfull.Th...
(Date:11/24/2009)..., WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNewsw...U.S.FoodandDrugAdministration(FDA)hasacceptedforre...Aricept®(donepezilHClextendedrelease)tabletsf...(AD).Thisnewhigherdoseformulationcontains23mgofdon...adeliverysystemthatallowsforgradualreleaseofthedru...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Blood flow metabolism mismatch predicts pancreatic tumor aggressiveness 9697 1Blood flow metabolism mismatch predicts pancreatic tumor aggressiveness 9697 2Schwarzeneggers Budget Cuts Force Closure of California AIDS Clearinghouse 55311 1Schwarzeneggers Budget Cuts Force Closure of California AIDS Clearinghouse 55311 2Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 1Minorities have poorer results higher rates of inappropriate surgery to prevent stroke 55308 2
...ll/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; TSX: ...n,endocrine therapy and oncology, today reported t...ruitment for its Phase 2 trial in ovarian cancer,w...one (LHRH) agonist,linked to doxorubicin. The deci...ent was taken following recent first stage data re...
...gual lozenge) developed to be the first sleep aid...hen patients awaken and have difficulty re...ranscept Pharmaceuticals,Inc., a privately-held sp...at it has submitted a New Drug Application (NDA) t...its lead product candidate, Intermezzo(R),(zolpide...
Other Medicine Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6
BD Visitec Infusion Cannulas
BD Beaver™ Accurate Depth Knives
BD Visitec Irrigating Cystomes
BD Visitec Irrigation and Aspiration Cannulas
Medicine Products: